What type of study is this?

This is a Human Clinical Trial study (also classified as: In Vitro Study).

Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma

View Full Paper

Ask AI

Bookmark

Authors

Combination treatment improves tumor growth outcomes in NRAS-mutant melanoma, suggesting a new therapeutic strategy against drug resistance.

Combination treatment significantly reduces tumor growth in NRAS-mutant melanoma cases, indicating its potential efficacy.
Therapeutic approach uses brimarafenib and mirdametinib to target MAPK signaling, leading to apoptosis.
In vitro and in vivo experiments confirm strong inhibition of patient-derived NRAS-mutated melanoma cell lines.
Results highlight the combination's ability to combat drug resistance and prolong survival in lab models.

Tellenbach et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Combination treatment improves tumor growth outcomes in NRAS-mutant melanoma, suggesting a new therapeutic strategy against drug resistance.